Bezafibrate Upregulates Mitochondrial Biogenesis and Influence Neural Differentiation of Human-Induced Pluripotent Stem Cells

Justyna Augustyniak1 · Jacek Lenart2 · Paweł Gaj3 · Monika Kolanowska4 · Krystian Jazdzewski3,4 · Piotr Pawel Stepień5,6,7 · Leonora Buzanska1

Received: 27 April 2018 / Accepted: 27 September 2018 / Published online: 13 October 2018
© The Author(s) 2018

Abstract

Bezafibrate (BZ) regulates mitochondrial biogenesis by activation of PPAR’s receptors and enhancing the level of PGC-1α coactivator. In this report, we investigated the effect of BZ on the expression of genes (1) that are linked to different pathways involved in mitochondrial biogenesis, e.g., regulated by PPAR’s receptors or PGC-1α coactivator, and (2) involved in neuronal or astroglial fate, during neural differentiation of hiPSC. The tested cell populations included hiPSC-derived neural stem cells (NSC), early neural progenitors (eNP), and neural progenitors (NP). RNA-seq analysis showed the expression of PPARA, PPARD receptors and excluded PPARG in all tested populations. The expression of PPARGC1A encoding PGC-1α was dependent on the stage of differentiation: NSC, eNP, and NP differed significantly as compared to hiPSC. In addition, BZ-evoked upregulation of PPARGC1A, GFAP, S100B, and DCX genes coexist with downregulation of MAP2 gene only at the eNP stage of differentiation. In the second task, we investigated the cell sensitivity and mitochondrial biogenesis upon BZ treatment. BZ influenced the cell viability, ROS level, mitochondrial membrane potential, and total cell number in concentration- and stage of differentiation-dependent manner. Induction of mitochondrial biogenesis evoked by BZ determined by the changes in the level of SDHA and COX-1 protein, and mtDNA copy number, as well as the expression of NRF1, PPARGC1A, and TFAM genes, was detected only at NP stage for all tested markers. Thus, developmental stage-specific sensitivity to BZ of neurally differentiating hiPSC can be linked to mitochondrial biogenesis, while fate commitment decisions to PGC-1α (encoded by PPARGC1A) pathway.

Keywords Bezafibrate · Mitochondrial biogenesis · hiPSC · NSC · PPAR’s · PGC-1α

Abbreviations

ACTB Actin beta
bFGF Basic fibroblast growth factor
BZ Bezafibrate
CAPN10 Calpain 10, calcium-activated neutral proteinase 10

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12035-018-1368-2) contains supplementary material, which is available to authorized users.

Leonora Buzanska
buzanska@imdik.pan.pl

1 Stem Cell Bioengineering Unit, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland
2 Department of Neurochemistry, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland
3 Laboratory of Human Cancer Genetics, Centre of New Technologies, University of Warsaw, Warsaw, Poland
4 Genomic Medicine, Medical University of Warsaw, Warsaw, Poland
5 Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland
6 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
7 Centre of New Technologies, University of Warsaw, Warsaw, Poland
| Protein ID | Description                                      | Protein ID | Description                                      |
|------------|--------------------------------------------------|------------|--------------------------------------------------|
| CCNG1      | Cyclin G1                                        | NF200      | Neurofilament 200                                 |
| CHAT       | Choline O-acetyltransferase                       | NQO1       | NAD(P)H quinone dehydrogenase 1                   |
| MT-CO1     | Mitochondrially encoded cytochrome c oxidase I (COX-1) | NP         | Neural progenitors                                 |
| CREB1      | cAMP-responsive element-binding protein 1        | NRF1       | Nuclear respiratory factor 1                      |
| DCFHDA     | Dichloro-dihydro-fluorescein diacetate            | NFE2L2 (NRF2) | Nuclear factor, erythroid 2-like 2 |
| CSPG4      | Chondroitin sulfate proteoglycan 4               | NSC        | Neural stem cells generated from hiPSC           |
| DCX        | Doublecortin                                     | OXPHOS     | Oxidative phosphorylation                         |
| EEF1A1     | Eukaryotic translation elongation factor 1 alpha 1 | PHB        | Prohibitin                                        |
| EGF        | Epidermal growth factor                           | POLG       | DNA polymerase gamma, catalytic subunit           |
| EGF        |                                                    |            |                                                  |
| EID2       | EP300-interacting inhibitor of differentiation 2  | POU5F1     | POU class 5 homeobox 1                            |
| eNP        | Early neural progenitors                          | PPARA      | Peroxisome proliferator-activated receptor alpha  |
| ERRs       | Estrogen-related receptors                        | PPARD      | Peroxisome proliferator-activated receptor delta  |
| ESR1       | Estrogen receptor 1                               | PPARG      | Peroxisome proliferator-activated receptor gamma  |
| ETC        | Electron transport chain                          | PPARGC1A   | Peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) |
| FAO        | Fatty acid oxidation                              | PPARC1B    | PPARG coactivator 1 beta                          |
| FASN       | Fatty acid synthase                               | PPRE       | Peroxisome proliferator response element          |
| GAD1       | Glutamate decarboxylase 1                         | PQQ        | Pyrroloquinoline quinone                          |
| GAPDH      | Glyceraldehyde-3-phosphate dehydrogenase          | PRKAA1     | Protein kinase AMP-activated catalytic subunit 1 alpha |
| GFAP       | Glial fibrillary acidic protein                   | RABEP2     | Rabaptin, Rab GTase-binding effector protein 2    |
| hESC       | Human embryonic stem cells                        |           |                                                   |
| hiPSC      | Human-induced pluripotent stem cells              | ROS        | Reactive oxygen species                           |
| HPRT1      | Hypoxanthine phosphoribosyltransferase 1          | RPLP0      | Ribosomal protein lateral stalk subunit 0         |
| IDB        | Idebenone                                        | RXRA       | Retinoid X receptor alpha                          |
| Ki67       | Proliferation marker protein Ki-67                | RXRB       | Retinoid X receptor beta                          |
| MAP 2      | Microtubule-associated protein 2                  | RXRG       | Retinoid X receptor gamma                          |
| mESC       | Mouse embryonic stem cells                        | qRT-PCR    | Quantitative reverse transcription PCR             |
| MYC-V      | Muc avian myelocytomatosis viral oncogene homolog | S100B      | S100 calcium-binding protein B                     |
| NANOG      | Homeobox protein NANOG                            | SCLO2B1    | Solute carrier organic anion transporter family, member 2B1 |
| NAT1       | N-Acetyltransferase 1                             | SDHA       | Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial |
| NCOR1      | Nuclear receptor corepressor 1, thyroid hormone- and retinoic acid receptor-associated corepressor 1 | SERPIN1    | Serpin family A number 1                          |
| ND1        | Mitochondrially encoded NADH-ubiquinone oxidoreductase core subunit 1 (mt-ND1) | SIRT1      | Sirtuin 1                                         |
| ND5        | Mitochondrial membrane respiratory chain NADH-ubiquinone oxidoreductase chain 5 (mt-ND5) | SLC1A1     | Solute carrier family 17 member 7                |
| NEFL       | Neurofilament, light polypeptide                  | SLC1A2     | Solute carrier family 1 member 2                  |
| NEFM       | Neurofilament, medium polypeptide                 | SLC1A3     | Solute carrier family 1 member 3                  |
| NEFH       | Neurofilament, heavy polypeptide                  | SLC6A4     | Solute carrier family 6 member 4                  |
| NES        | Nestin                                           | SLC17A7    | Solute carrier family 17 member 7                 |
| NEUROD1    | Neuronal differentiation 1                        | SOX2       | Transcription factor SOX-2                        |
|            |                                                   | TBP        | TATA box-binding protein                           |
Introduction

The fibrates groups of drugs, derivatives of dehydrocholic acid, are clinically used in the treatment of lipid disorders [1, 2]. Clofibrate, gemfibrozil, bezafibrate, fenofibrate, and ciprofibrate are therapeutically useful examples of drugs belonging to the fibrate family [2]. The effect of fibrates on fatty acid and lipoprotein metabolism was examined in detail in the literature [2]. The effect of fibrates on fatty acid metabolism is mediated by peroxisome proliferator-activated receptor (PPAR) receptors, which have agonist activity for peroxisome proliferator-activated receptor (PPAR)α, nuclear receptors involved in the transcription of genes involved in fatty acid oxidation, apolipoprotein production, and cholesterol transport, with additional functions in inflammation, endothelial function, and vascular remodeling [3].

Bezafibrate (BZ) was used in this study due to its identified influence on mitochondrial biogenesis [4]; however, information on the effect of BZ on the process of neural cell differentiation is very scarce, only a few publications describing the influence of this group of compounds on the nervous system [5].

The aim of our work was to check whether BZ, through the stimulation of mitochondrial biogenesis, can modulate the process of differentiation of neural cells at early stages of neural differentiation. At the molecular level, the effects of BZ are mediated by the activation of PPAR receptors that regulate the expression of genes involved not only in lipid homeostasis and energy metabolism but also many other processes, including inflammation, cellular differentiation, and proliferation [2]. PPAR-peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) encoded by PPARGC1A gene is considered the major regulator of mitochondrial biogenesis, also playing a role in the regulation of expression of antioxidant defenses [6–8]. Considering that PGC-1α leads to mitochondrial biogenesis, several studies have evaluated BZ as a potential pharmacological strategy for neurodegenerative disorders characterized by mitochondrial dysfunction. Human-induced pluripotent stem cells (hiPSC) hold great potential in the field of regenerative medicine, disease modeling, and drug screening. More and more evidence shows that mitochondria play a fundamental role in the process of differentiation. hiPSC rely mainly on aerobic glycolysis for energy production, and mitochondria display an immature phenotype and reduced activity. Upon the initiation of differentiation, a switch from glycolysis to oxidative phosphorylation occurs in the differentiating cells because the more specialized cells have a greater demand for ATP. mtDNA copy number seems to be an important factor for the appropriate initiation of differentiation.

The starting population of hiPSC present the phenotype of ESC-like state with high self-renewal and differentiation potency in vitro and in vivo. In the defined culture condition, hiPSC have the ability to differentiate into neurons, astrocytes, and oligodendrocytes [9, 10]. In our in vitro study, we used neural stem cells (NSC), early neural progenitors (eNP), and neural progenitors (NP) derived from hiPSC (Fig. 1). We have shown that three cell populations obtained during early neural differentiation of hiPSC reveal distinct characteristic and differ significantly on the level of transcription of genes encoding pluripotency and neural differentiation markers. The cell phenotype was confirmed by immunofluorescence staining, RTPCR, and RNA-seq [11, 12].

In this report, we aimed to answer the question whether upregulation of mitochondrial biogenesis by BZ in hiPSC can be related to the regulation of their neural fate commitment. Based on RNA-seq data, we investigated the expression of genes that are linked to different pathways involved in mitochondrial biogenesis, e.g., regulated by PPAR’s receptors or PGC-1α coactivator, during neural differentiation of hiPSC. We tested also the influence of three different concentrations of BZ on the viability, mitochondrial membrane potential, ROS level, total cell number, and mitochondrial biogenesis revealed by the level of SDHA and COX-1 protein. The efficient highest concentration of BZ was further chosen to test mitochondrial biogenesis at mRNA level (NRF1, TFAM, PPARGC1A) gene expression (qRT-PCR) and mtDNA copy number (qPCR) assay. The phenotypic changes during neural differentiation were controlled by the analysis of gene expression (qRT-PCR) of the main neuronal markers: MAP2, DCX, and the astrocytic markers: GFAP, S100B. Our results indicated that upregulation of mitochondrial biogenesis and sensitivity to BZ of hiPSC is dependent upon the stage of neural development, while fate commitment decisions are linked to PGC-1α (encoded by PPARGC1A) pathway.

Materials and Methods

Cell Culture and BZ Treatment

hiPSC (Gibco® Human Episomal iPSC Line, Life Technologies, Thermo Fisher Scientific) were differentiated into NSC, eNP, and late NP in accordance with the protocol of [13] with some modifications as described previously [11, 12]. hiPSC at the undifferentiated stage of development were
cultured in Essential 8 Medium (Thermo Fisher Scientific) on a 6-well plate covered with rh-Vitronectin (Thermo Fisher Scientific) with medium replaced every day. For the experiments, the cells were seeded on a plate covered with a solution of Matrigel: DMEM/F12, 1:30 ratio (BD Matrigel™ Basement Membrane Matrix, BD Biosciences) at density 5 × 105 cells/cm2 on 6-well, 24-well, or 96-well (Nunc) plates. On the next day, cells were treated with BZ (Sigma-Aldrich) in the concentrations 0 μM, 12.5 μM, 25 μM, and 50 μM in medium dedicated to the neural stage of differentiation: NSC (Neurobasal, Neural Induction Supplement 1:50, Advanced DMEM, 1:1, AAS 1:100), eNP (Neurobasal, DMEM/F12 [1:1], N2 supplement 1%, B27 supplement 1%, EGF [20 ng/mL], bFGF [20 ng/mL]), and NP (Neurobasal, DMEM/F12 [1:1], N2 supplement 1%, B27 supplement 1%). After 5 days of exposition to BZ, samples were taken to evaluate its effects on the cells at the specific stage of development. The phenotype of the control populations used in the experiments of this study was characterized before exposition to BZ by RT-PCR, RNA-seq, and immunocytochemistry staining methods as previously described [11, 12].

### Alamar Blue Viability Assay

Cell viability was measured on the fifth day of BZ exposition at the following concentration range: 0 μM, 12.5 μM, 25 μM, 50 μM. Afterwards, the medium was changed to fresh one containing resorufin (1:10 ratio). After 3 h of incubation, the fluorescence at excitation 544 nm and emission 590 nm wave lengths were measured using a plate reader (Fluoroscan Ascent, FL, Labsystems). Data were normalized to total cell number with Janus green staining according to the manufacturer’s protocol. The results are shown as the [%] of control.

### ROS Level

After 5 days of exposure to BZ, the medium was changed to fresh one containing (1 μM) of DCFHDA (dichloro-dihydro-fluorescein diacetate, Sigma-Aldrich). Three hours later, the fluorescence intensity (DCF) (485 nm excitation–538 nm emission) was recorded using a plate reader (Fluoroscan Ascent FL, Labsystems) as described previously [11, 12]. Normalization of data to the total cell number was performed by Janus green staining according to the manufacturer’s protocol. Results were calculated as the ratio [%] of the test samples to the untreated control.

### Mitochondrial Membrane Potential

Mitotracker® Red CMXRos (Thermo Fisher Scientific) staining was used to determine mitochondrial membrane potential in NSC, eNP, and NP populations exposed to BZ as described previously [11, 12]. On day 5, the medium was changed to fresh one supplemented with 50 nM Mitotracker® Red CMXRos. Four hours later, fluorescence at excitation 579 nm and emission 599 nm was measured with a plate reader (Fluoroscan Ascent FL, Labsystems). The results are shown as the ratio [%] of the test sample to the untreated control after normalization to cell number with Janus green staining according to the manufacturer’s protocol.

### SDHA, COX-1 Protein Level, and Proliferation Ratio Determination

Levels of SDHA and COX-1 (MT-CO1) proteins were evaluated with MitoBiogenesis™ In-Cell ELISA Kit (Abcam) on FluoStar plate reader (OMEGA, BMG LABTECH), according to the manufacture’s protocol, after 5 days of exposure to BZ. The results are shown in the graph as the [%] of the untreated control. The total number of cells was determined with Janus green and calculated from a standard curve. The details of the measurement have been described previously [11, 12].

### Isolation of Nucleic Acids

Total RNA and DNA were extracted from NSC, eNP, and NP cells using ZR-Duet™ DNA/RNA MiniPrep Kit (Zymo Research). RNA was purified using Clean-Up RNA Concentrator kit (A&A Biotechnology). After purification, RNA integrity was assessed by electrophoresis on 2% agarose
gels. The concentration of RNA and DNA was determined by using NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). The DNA was used in the mtDNA copy number analysis (qPCR). The RNA was converted into cDNA in the RT reaction (High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher Scientific) on Civic Cycler Thermal cycler (Biotech INC). cDNA then was used to analyze gene expression (qRT-PCR).

Primer Design

All primers used in these studies base on the human reference genome GRCh38 and were designed, with Primer-BLAST software (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), and analyzed in silico and in vitro. Sequences of primers used here were described previously [11, 12]. Experimentally determined PCR efficiency E (%) was in the range 1.92–2.15.

qPCR

For qPCR, 10 ng of DNA was loaded with 0.25 μM of forward and reverse primers 12.5 μL of iTaq™. Universal SYBR® Green Supermix (Bio-rad) onto a 96-well plate for LightCycler® 96 (Roche Diagnostics GmbH) at the PCR reaction conditions: hot start at 95 °C for 3 min followed by 45 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. The mtDNA copy number was calculated as (1) ND1/SCLO2B1 and (2) ND5/SERPINA1 ratio on the quantification cycle (Cq) values and the baseline settings automatically calculated by the qPCR instrument software. Sequences of primers used here are shown in Table 1.

qRT-PCR

For qRT-PCR, 10 ng of cDNA was loaded with 0.25 μM of forward and reverse primers; 12.5 μL of iTaq™ Universal SYBR® Green Supermix (Bio-rad) onto a 96-well plate for LightCycler® 96 (Roche Diagnostics GmbH) in the following steps: initial denaturation step at 95 °C for 3 min, 45 cycles of denaturation at 95 °C for 10 s, and annealing/extension at 58 °C for 1 min. Samples were tested in four replicates. The Cq values automatically calculated by the qPCR instrument software were then used for data analysis GeneEx 6.1 software (MultiD Analyses AB). Relative gene expression was determined using the ΔΔCT method [14]. NormFinder was used for reference gene prediction (Fig. 6). Sequences of primers used in these experiments are shown in Table 2.

RNA-seq

Sequencing was performed with the use of NextSeq 500/550 High Output Kit-75 cycles (cat. no. FC-404-2005, Illumina, USA) on NextSeq 500 sequencer (Illumina, USA). The libraries were subjected to sequencing using the Illumina NextSeq 500 76 bp single-end mode. Before using in statistical analysis, the raw RNA-seq data (FASTQ) was trimmed for adapter sequences and filtered using Trimmomatic [15]. Then the reads were mapped with STAR [16] (aligner using the reference genome (GRCh38) coupled with Ensembl 88 transcriptome annotations). Transcription levels were calculated using HTseq-count [17, 18] and were further used for differential gene expression (DGE) analysis using edgeR [19]. Data are presented as normalized counts per million (log2) and differential gene expression results. The details of the measurement have been described previously [11, 12]. The expression of genes participating in mitochondrial biogenesis regulation and the PPAR and PGC-1α signaling pathways is presented in the form of “heat map” which was built based on the software MORPHEUS (Broad Institute, https://software.broadinstitute.org/morpheus/).

Analysis In Silico

In silico analysis with Genemania web-tool (https://genemania.org/) was applied to build up predicted network of interactions between genes involved in PGC-1α pathway and neuronal differentiation. The performed analysis and detailed sources are provided in Supplementary Data 2.

Table 1 Primmers used for qPCR

| Gene symbol | GenBank number | Primer sequence | Amplicon length (bp) |
|-------------|----------------|-----------------|---------------------|
| ND1 F       | NC_012920.1    | TACGGGCTACTACAACACCCTTC | 77                  |
| ND1 R       |                | ATGGTAGATGTGGGGTTT | 70                  |
| ND5 F       | NC_011137.1    | CATTACTAACAACATTTCCCGC | 70                  |
| ND5 R       |                | GGGCTGTGAGTTTTAGGTAGAGGG | 70                  |
| SERPINA1 F  | NM_000295.4    | CAGTGAATAAATGAGGCGTACATCC | 89                  |
| SERPINA1 R  |                | GACTGTTTTCATGCGCTCTGGAAGG | 89                  |
| SLCO2B1 F   | NM_007256.4    | CCTGATGCTAGGTGTTCTTTTCTTG | 85                  |
| SLCO2B1 R   |                | GGTCACTGCGCTACCTAGAAC | 85                  |

F forward, R reverse
Statistical Analysis

Statistical analysis of the results was carried out using the GraphPad Prism 5.0. (LaJola, USA) software. The Kolmogorov-Smirnov test was used as the normality assay. The statistical significance between samples vs. control was obtained with Student’s t test or one-way ANOVA with Tukey’s post-test. A statistical significance between groups

| Primers  | GenBank number | Primer sequence | Amplicon length |
|----------|----------------|-----------------|-----------------|
| ACTB F   | NM_001101.3    | GCTCACCATGGATGATGATATCGC | 169             |
| ACTB R   |               | CACATAGGAAATCCTCTCTGGAACCAT |             |
| CAPN10 F | NM_023083.3    | TCTCACCCGCTACTACCTG | 86              |
| CAPN10 R |               | CCGGCTAGAGAAGACCTCGGA |             |
| CCNG1 F  | NM_004060.3    | GCCTCTCGGATCTGATACGT | 138             |
| CCNG1 R  |               | CATTCACTGTTCATGACCTG |             |
| DCX F    | NM_000555.3    | GGAAAGGGGTTGATGAAATAGCACAACAA | 122          |
| DCX R    |               | AAGCCCTCTTTTCTCTCAATAATGTC |             |
| EEF1A1 F | NM_001402.5    | TGGTCTCTTTGTGCAACCCCA |             |
| EEF1A1 R |               | ACAACCCCTTCTCCACCCA |             |
| EID2 F   | NM_153232.3    | GGCATCGCTCTGCTCAGTTA | 74             |
| EID2 R   |               | C TTCAGCTGCAATCACATGACC |             |
| GAPDH F  | NM_002046.5    | GTTCGACAGTCAGCCGACTC | 90              |
| GAPDH R  |               | TCCTTCACACTACATCCCTTG |             |
| GFAP F   | NM_002055.4    | GTGAAAGCCTGGAGATGCG | 76              |
| GFAP R   |               | TGCCCTGACTCCGACCTC |             |
| HPRT1 F  | NM_000194.2    | AGGCCGAACCTCTGCCCTTC | 166             |
| HPRT1 R  |               | CTGTTTCATCATCCTATACACGAC |             |
| MAP2 F   | NM_002374.3    | TGCCCTCAGAAACAGACTGCA | 101             |
| MAP2 R   |               | AAGCGTCAGCTGAGGGAAGGA |             |
| MYC F    | NM_002467.4    | CCCTCCACCTCGGAAGGACTA | 96              |
| MYC R    |               | GCTGTCTACATGGCTTGAGGGA |             |
| NAT1 F   | NM_001160170.3 | TGGTTGCGCTGAAATACAC | 93              |
| NAT1 R   |               | TCTGTCATAGGCACTTCCT |             |
| NRF1 F   | NM_001001928.2 | CAGCGCGCTCTGAAAGCTCAT | 148             |
| NRF1 R   |               | GTCATTCATGCACTGACATACTA |             |
| PHB F    | NM_001281496.1 | TGGAAAGCAGGGTGGAGGAGGAG | 76             |
| PHB R    |               | ATCATGGAGCAGGGAGGACT |             |
| PPIARGC1A F | NM_003201.2    | TAGTAAACAGAGTCCTCTGTTCC | 174             |
| PPIARGC1A R |               | CTCGTAGCTCTCCATACAGACTC |             |
| RABEP2 F | NM_024816.2    | AGAGAAGGGGCAATATGTTGAG | 96              |
| RABEP2 R |               | CAGCGTCATGGTTCTCTCTTCT |             |
| RPLP0 F  | NM_001000.2    | CTCGTGGAAGTGACATCTG | 76              |
| RPLP0 R  |               | CTGTCTCTCCCTGGCAGCCTAC |             |
| S100B F  | NM_006272.2    | CGGAAGGAAAACTGACTACA | 132             |
| S100B R  |               | TCTGCTAGGATGAGAAGACCG |             |
| TBP F    | NM_003194.4    | GCAAGGGTTTCTGTTTGGCC | 80              |
| TBP R    |               | CAAGGGCTTGGAGTGGTG |             |
| TFAM F   | NM_005011.4    | TGGAAAGATTCCCAAGAAGCTAAGGCTG | 132             |
| TFAM R   |               | TAAGAAGGTTGTGCTCCTTCTTAGCAT |             |
| TUBB3 F  | NM_006086.3    | CAACCCAGATCGGGCCAGGAAGTT | 146             |
| TUBB3 R  |               | GAGGCACGACTTGTGGTGAAGAAGA |             |
| UBC F    | NM_021009.6    | ACAGGGACTTTGCTGTAGCTCA | 82              |
| UBC R    |               | ATCCGGAGAAGGGACTACT |             |
| ZNF324B F | NM_207395.2    | CATTTGGAAGGACAAACACTGAGTATGAGT | 164             |
| ZNF324B R |               | CTTATCTGCTCCTCGAAGCTACTGTC |             |

F forward, R reverse
was obtained with two-way ANOVA, with Bonferroni post-test (*), p < 0.05. Results represent three independent experiments, each at least in four replicates. Results shown in the brackets were obtained as mean with (± SEM). Data in text were presented as mean with standard deviation (± SD).

Results

Characterization of Cell Populations

The three stages of hiPSC neural differentiation: NSC (neural stem cells), eNP (early neural progenitors), and NP (neural progenitors), were obtained according to the protocol presented on Fig. 1. The morphology of these cells at different stages are presented on contrast-phase images (Fig. 2a–d). These lineage-related control cell populations obtained by our group and used in this study (Figs. 1 and 2a–d) have been fully characterized using RT-PCR, RNA-seq, and immunocytochemistry and these data have been recently published [11, 12].

Expression of Selected Genes Involved in the Response to Bezafibrate

The expression of selected genes involved in the PPARs and PGC-1α pathways obtained with RNA-seq analysis are presented in the form of heat map on Fig. 2e. The panel of genes included PPARA, PPARD, PPARG, RXRA, RXRB, RXRG, PPARG1A, PPARG1B, NRF1, NFE2L2, ESR1, THRB, PRKAA1, SIRT1, NQO1, CREB1, POLG, TFAM, and FASN.

Out of the set of analyzed genes, only the expression of PPARG1A gene, which encodes PGC-1α, the main regulator of mitochondrial biogenesis, revealed the significant difference (FC > 2; p < 0.0001) between compared populations (NSC, eNP, NP vs. hiPSC and eNP, NP vs. NSC). The supplementary data (Supplementary Data 1) show the statistical evaluation of the comparison of expression of genes presented on the heat map (Fig. 2e) between analyzed cell populations.

Cell Viability

12.5 μM concentration of BZ did not have a significant effect on cell viability in all tested populations (Fig. 3a). A significant increase in viability (in relation to control) was recorded for the eNP stage of development at dose 25 μM (124.77% (± 10.21). The highest tested dose of BZ (50 μM) significantly increased viability of NSC (111.03% (± 9.87) and eNP (115.31% (± 0.03) (with regard to control). We did not observe significant changes in viability of NP cells exposed to BZ. For 25 μM, we noted significant difference in viability after exposition to BZ between eNP and NP, while for 50 μM between NSC and NP as well as eNP and NP. The results are shown in Fig. 3a.

ROS Level

BZ reduced ROS level significantly (with regard to control) in all tested populations (NSC, eNP, and NP). In the eNP population,
this decrease was significant at all tested doses: 12.5 μM (64.78% (± 5.33), 25 μM (85.61% (± 9.26), and 50 μM (75.12% (± 8.46). At the NSC stage of differentiation, significant reduction of the level of free radicals was recorded for doses 12.5 μM (87.20% (± 7.70)) and 50 μM (62.30% (± 16.22)). The strongest significant effect of BZ on ROS level in all tested populations was observed for dose 50 μM: NSC (62.30% (16.22)); eNP (75.17% (8.46)); NP (80.14% (± 6.96)). A significant difference between populations was noted only at dose 50 μM between NSC and NP. The data are shown in Fig. 3b. 

Mitochondrial Membrane Potential

BZ did not significantly change (relative to control) mitochondrial membrane potential (ΔΨm) in the population of NSC and eNP in any tested dose. A significant increase of ΔΨm was observed in the NP stage for doses 25 μM (126.62% (± 17.13)) and 50 μM (147.68% (± 10.35), but not for 12.5 μM (111.35% (± 1.01)). For 25 μM dose of BZ, a significant difference between eNP and NP cells was observed, while at 50 μM, NP vs. NSC and NP vs. eNP were significantly different (Fig. 3c).

Total Cell Number

We showed a significant influence of BZ on the total cell number (relative to control) in all tested cell populations only at the dose 50 μM; while in NSC and eNP, the total cell number was increased significantly (136.87% (± 20.50) and 110.00% (± 6.37) respectively), at the NP stage of development, the response to BZ was not significant (78.22% (± 12.41)). When different stages of development were compared, significant differences were observed for the 25 μM and 50 μM dose, and NSC revealed the highest increase in total cell number. At 25 μM, a significant difference was observed between NSC and NP and also between eNP and NP, while at 50 μM among NP vs. NSC; eNP vs. NSC; and NP vs. eNP (Fig. 3d).
Mitochondrial Biogenesis Evaluated at the Protein Level: SDHA and COX1

We observed a significant increase of SDHA protein level in NP cells treated with BZ vs. untreated control for all tested concentrations: 12.5 μM (107.59 (± 2.40)); 25 μM (109.49 (± 3.80)); 50 μM (109.52 (± 3.50)). BZ significantly enhanced the SDHA protein level in the eNP cells at doses 25 μM (107.61 (± 6.05)) and 50 μM (110.16 (± 1.57)). At the NSC stage of differentiation, BZ did not significantly affect the SDHA level in any of the tested concentrations. A significant difference: NP vs. NSC, was shown for 12.5 μM and 50 μM BZ. The difference between NSC and eNP was significant at dose 50 μM (Fig. 4a).

BZ significantly increased the COX-1 protein level in the eNP at all tested concentrations: 12.5 μM (124.79 (± 11.39)); 25 μM (127.02 (± 11.11)); 50 μM (121.24 (± 12.44), and in the NP at 50 μM (166.18 (± 37.96)). A significant difference between tested groups was detected between NSC and NP (Fig. 4b).

Relative mtDNA Copy Number

Relative mtDNA copy number was calculated as the (A) ND1/SCLO2B1 ratio and (B) ND5/SERPINA1 ratio, where ND1 and ND5 are encoded by mitochondrial genome and SCLO2B1 and SERPINA1 are encoded by nuclear genome. BZ significantly increased the ratio of ND1/SCLO2B1 from 47.67 (± 3.09) to 74.50 (± 10.71) in NP stage. Relative mtDNA copy number in the NSC, eNP, and NP populations treated with BZ did not differ significantly between the tested groups (Fig. 5a).

BZ significantly enhanced the relative mtDNA copy number measured as the ND5/SERPINA1 ratio only in the NP stage of differentiation from 70.50 (± 7.50) to 110.00 (± 8.00), when control to treated cells were compared. Comparison of starting, untreated cell populations revealed significant difference: NSC vs. eNP. BZ-treated populations were significantly different for eNP vs. NSC and NP vs. NSC (Fig. 5b).
Validation of Reference Genes for qRT-PCR

NormFinder was used to rank the tested genes according to their average expression stability value from the most stable expression (lowest SD value) to the least stable expression (highest SD value). The ranking of the 16 potential housekeeping genes according to their expression stability values is shown in Fig. 6a, c, e. The lowest values correspond to the most stable gene expression. To obtain the optimal number of housekeeping genes for normalization in RT-qPCR relative gene expression in NSC cells (Fig. 6b), eNP cells (Fig. 7d) and NP cells (Fig. 6f), accumulated standard deviation (Acc. S.D) calculation was performed. Thirteen genes (TBP, TUBB3, CCNG1, GAPDH, UBC, ACTB, PHB, EID2, ZNF324B, EEF1A1, RPLP0, RABEP2, and CAPN10) were selected as reference genes for the NSC (Fig. 6b). For the NP and eNP, two reference genes were predicted by NormFinder program. These are TBP and EID2 or GAPDH and EID2, respectively.

Relative Gene Expression Involved in Regulation Mitochondrial Biogenesis and Neural Differentiation

Expression of the key genes controlling mitochondrial biogenesis: NRF1, TFAM, and PPARGC1A, and genes involved in neural (DCX, MAP2) and glial (GFAP, S100B) differentiation was tested using qRT-qPCR. BZ exposition results with upregulation of NRF1 gene expression at all tested neural stages of development. NRF1 mRNA expression level was
enhanced; about 2-fold at the stage of early neural progenitors (1.79 (± 0.22)), about 1.5-fold at NSC (1.53 (± 0.15)), and about 1-fold at NP (0.79 (± 0.34)). A significant difference of relative \( \text{NRF1} \) gene expression was detected: NP vs. NSC and NP vs. eNP (Fig. 7a).

\( \text{PPARGC1A} \) expression level was increased about 6-fold in NSC exposed to BZ (50 \( \mu \text{M} \)) compared to the untreated control. In eNP and NP, upregulation of \( \text{PPARGC1A} \) gene expression about 5-fold in eNP (5.45 (± 0.84)) and about 0.3-fold in NP (0.35 (± 0.32)) was observed. Significant difference in \( \text{PPARGC1A} \) gene expression was noted: NP vs. NSC and NP vs. eNP (Fig. 7b).

\( \text{TFAM} \) expression level after BZ treatment was different at specific stages of neural development. It was downregulated in the NSC (−1.16 (± 0.22)) and eNP (−0.625 (± 0.244)) population while in NP (0.92 (± 0.30)), upregulation was observed. A significant difference was detected: eNP vs. NSC; NP vs. NSC; and NP vs. eNP (Fig. 7c).

\( \text{MAP2} \) gene expression was downregulated upon BZ treatment at all tested populations; however, the strongest downregulation was observed in the eNP (−1.71 (± 0.59)) and in the NP (−1.01 (± 0.54)) stages. At NSC stage of development, this downregulation was not significant (0.08 (± 0.21)). When the obtained data were compared between different stages, significant difference between \( \text{MAP2} \) relative gene expression was observed in NP vs. NSC and eNP vs. NSC (Fig. 7d).

\( \text{DCX} \) gene expression was upregulated in all population after treatment in BZ, for eNP (2.28 (± 1.21)) and for NSC (1.91 (± 0.28)). The strongest effect of BZ exposition for \( \text{DCX} \) expression was observed in the NP cells (± 9.14 (0.39)). The difference in relative gene expression of \( \text{DCX} \) as the response to BZ was observed between NP vs. NSC and NP vs. eNP, but not between eNP vs. NSC (Fig. 7e).

\( \text{GFAP} \) mRNA expression level was enhanced by BZ (50 \( \mu \text{M} \)) treatment about 6-fold (6.06 (± 0.20)) in NSC and about 4-fold (3.72 (± 0.68)) in eNP, while was not

---

Fig. 7 Relative gene expression (fold of changes vs. control) was determined in NSC, eNP, and NP cells after 5 days exposition to BZ (50 \( \mu \text{M} \)) by qRT-PCR methods. Relative gene expression was evaluated for key genes connected with regulation of mitochondrial biogenesis: a \( \text{NRF1} \), b \( \text{PPARGC1A} \), and c \( \text{TFAM} \); neuronal: d \( \text{MAP2} \) and e \( \text{DCX} \); and astrocytic: e \( \text{GFAP} \) and f \( \text{S100B} \) differentiation. Results presented in the brackets are represented as the mean value (± SEM). Brackets show statistically significant differences between NSC, eNP, and NP obtained with one-way ANOVA with Tukey’s post-test: (*), \( p < 0.05 \)
downregulated at NP (−1.94 (± 0.39)) as compared to untreated control. Upon BZ treatment, GFAP relative gene expression was different at tested stages of development. Significant differences were noted between relative GFAP expression in the eNP vs. NSC and NP vs. eNP (Fig. 7f).

The S100B gene expression was increased significantly after exposition to BZ in all tested populations: NSC (5.73 (± 0.570)); eNP (4.15 (± 0.295)); and NP (10.89 (± 1.83)) (Fig. 7g). The strongest upregulation of S100B gene was in the NP population. S100B relative gene expression level after BZ exposition was different at specific stages of neural development eNP vs. NSC; NP vs. NSC; and NP vs. eNP.

The summary of the results (presented in Table 3) indicated that only at the NP stage of differentiation all the parameters indicating mitochondrial biogenesis were upregulated upon stimulation by BZ.

### Analysis In Silico by Genemania

To determine the interrelationship between genes coding PPAR receptors (PPARA, PPARD, PPARG), PAPRGC1A and markers of neural cells (NES), neuronal cells (DCX, NEFL, NEFM, NEFH, TH, CHAT, SLC17A7, SLC1A1, GAD, SLC6A4), astrocytic markers (ALDH1L1, SLC1A3, SLC1A2, S100B), and oligodendrocyte marker (CSPG4), Genemania network analysis was applied, the results of which are displayed in Fig. 8. The derived network consisted of 22 of core genes and 15 additional genes that were pulled in by Genemania. In our research, we focused on gene expression studies. Genemania showed also the relationships in pathways, shared protein domains, co-localization, and co-expression between analyzed genes and their products. Detailed results are presented in Fig. 8.

### Discussion

In this report, we aimed to answer the question whether up-regulation of mitochondrial biogenesis by BZ in hiPSC can be related to the regulation of their neural fate commitment.

The question addressed in this study was whether BZ can influence neural differentiation of hiPSC and whether the cellular response depends upon the stage of neural development. Since BZ is a well-known drug influencing mitochondrial biogenesis [4], we aimed to find out whether upregulation of mitochondrial biogenesis by BZ in hiPSC is developmental stage specific and can be linked to the regulation of their neural fate commitment. We investigated the cellular and molecular responses to BZ at three different stages of neural differentiation, covering the early developmental period: NSC, eNP, and NP obtained from human iPSC. It is important to note that NSC, eNP, and NP were shown to differ significantly in terms of expression of NES, MAP2, and GFAP [11]. The hiPSC-derived NSC, eNP, and NP model which we used in the BZ study was previously investigated by us in the PQQ and IDB study [11, 12]. All our experiments have shown developmental stage-dependent sensitivity of hiPSC in response to the factors involved in mitochondrial biogenesis (PQQ, IDB, and BZ); however, while PQQ and IDB treatment specifically enhanced mitochondrial biogenesis in eNP stage of development, BZ treatment was the most potent at NP stage.

### Table 3 Summary of the influence of bezafibrate (50 μM) on NSC, eNP, and NP

|                          | NSC | eNP | NP       |
|--------------------------|-----|-----|----------|
| Viability                | ↑ (*)| ↑ (*)| ↓ (ns)   |
| ROS level                | ↓ (*)| ↓ (*)| ↓ (*)    |
| Mitochondrial membrane potential | ↓ (ns) | ↓ (ns) | ↑ (*)    |
| Total cell number        | ↑ (*)| ↑ (*)| ↓ (*)    |
| Protein expression       | SDHA| ↓ (ns)| ↑ (*)    |
|                          | COX-1| ↓ (ns)| ↑ (*)    |
| mtDNA copy number        | ND1/SCLO2B1 ratio| ↓ (ns)| ↑ (*)    |
|                          | ND5/SERPINA1 ratio| ↓ (ns)| ↑ (*)    |
| Gene expression (fold of change) | NRF1| ↑ (1.53)| ↑ (1.79)| ↑ (0.79) |
|                          | TFAM| ↓ (−1.16)| ↓ (−0.63)| ↑ (0.92) |
|                          | PPARGC1A| ↑ (6.39)| ↑ (5.45)| (0.35)   |
|                          | MAP2| ↓ (−0.08)| ↓ (−1.71)| ↓ (−1.01) |
|                          | DCX | ↑ (1.91)| ↑ (2.28)| (9.137)  |
|                          | GFAP| ↑ (6.06)| ↑ (3.72)| ↓ (−1.94) |
|                          | S100B| ↑ (5.73)| ↑ (4.15)| (10.89)  |

NSC: neural stem cells, eNP early neural progenitors, NP late neural progenitors, ns not significant, ↑ upregulation, ↓ downregulation

*p < 0.05
Our results indicate that BZ enhances the expression of PPARGC1A gene in a stage-specific manner and it is not directly linked to its influence on mitochondrial biogenesis. The highest upregulation of PPARGC1A upon in silico modeling the interaction between selected genes involved in PGC-1α pathway and neuronal differentiation. The in silico analysis of function and interaction between PPAR receptors (PPARA, PPARD, PPARG), coactivator PPARGC1A gene and neural (NES), neuronal (DCX, NEFL, NEFM, NEFH), neuronal subtypes (TH, CHAT, SLC17A7, SLC1A1, GAD1, SLC6A4), as well as astrocyte (ALDH1L1, SLC1A3, SLC1A2, S100B) and oligodendrocyte (CSPG4) markers was performed in the Genemania web tool (https://genemania.org/) to show the networks of interaction between the selected genes (cytoscape). The in silico evaluation present function of analyzed genes and network of interactions between them. Within the function category, analyzed genes were divided into the following groups: neuron projection (NEFH, NEFM, BEFL, DCX, TH); intermediate filament cytoskeleton (NES, NEFH, NEFL); intracellular receptor signaling pathway (PPARA, PPARD, PPARG, PPARGC1A); S100B protein binding (S100B); regulation of neurotransmitter level (CHAT, SLC17A7, SLC1A3, SLC6A4, GAD1); carboxylic acid transport (PPARA, PPARG, PPARD, SLC1A3, SLC17A7, SLC1A1, SLC1A2). Within the network category analyzed genes were divided, based on the type of interaction, to the following groups: physical interaction (1.41%), prediction (63.88%), genetic interaction (0.33%), shared protein domains (12.06%), co-localization (3.71%), co-expression (17.75%), and pathway (0.86%).
BZ treatment was observed at the NSC and eNP stage of differentiation and was accompanied by the upregulation of GFAP, similarly to other drugs (PQQ, IDB) tested previously by our group [11, 12]. Alongside other astrocytic markers, S100B was upregulated by BZ in all tested cell populations with the strongest effect in the NP stage. As mentioned above, the significant upregulation of mitochondrial biogenesis upon BZ treatment was also observed at NP stage of differentiation. Taken together, this data and from our previous studies may suggest that induction of mitochondrial biogenesis positively influence expression of astroglial markers. However, in case of BZ, and its influence on GFAP expression, such association does not exist. It is worth to note that in all our studies, upregulation of astrocytic markers coexists with upregulation of PPARGC1A and this is linked with downregulation of MAP2 regardless of developmental stage-specific induction of mitochondrial biogenesis. Thus, our data suggest the key role of PGC-1α pathway in the regulation of the early neuronal and astrocytic fate commitment. The in silico analysis showed that main role of PPARGC1A genes was related with involving in the PPAR receptor intracellular signaling pathway. PPARGC1A gene participates in the network connected with neural development but directly interacts only with the PPARA and PPARG genes. The interaction of PPARGC1A with other elements of the network should be deeply analyzed, since up to now it has not been sufficiently understand.

The correlation of astrocytic induction with PGC-1α expression was described previously in glioblastoma cells. Xing and colleagues [20] showed that PGC-1α-deficient glioblastoma cell line treated with N6,2′-dibutyryladenosine 3′,5′-cyclic monophosphate (dbcAMP) was characterized by abrogated induction of GFAP expression, mtDNA content, and oxygen consumption rate (OCR), while overexpression of PGC-1α was linked to enhanced GFAP expression, mtDNA content, and OCR. Other studies indicated that stimulating mitochondrial biogenesis in mouse pluripotent stem cells (mESC) reduces pluripotency and favors cell differentiation or commitment to specific lineages [21]. Thus, we suspect that modulation of the specific pathway which controls mitochondrial function may stimulate commitment to specific neural lineages.

It was documented that adult mouse neural stem cells possess all three PPAR isotypes with nuclear localization which suggested their important role in process of neural differentiation as transcription factors [22]. However, the activity of these receptors has not been examined. To our knowledge, no literature data showing the expression and activity of PPAR receptors in the human NSC were reported.

Our RNA-seq data revealed significant upregulation of expression PPARGC1A in NSC, eNP, and NP in control populations as compared to hiPSC (Supplementary Table 1). The PPARGC1A gene is one of the most important factors which control mitochondrial biogenesis in the cells [23]. TFAM gene expression was downregulated during hiPSC neuronal differentiation [11]. The treatment with BZ reversed TFAM expression profile: the highest upregulation was observed in NP stage of differentiation, which is consistent with the induction of other markers of mitochondrial biogenesis upregulated upon BZ treatment only in NP stage.

Studies of other groups suggested also potential role of PPAR’s specific isoforms in the regulation of cell proliferation, death, and differentiation [22] but information on the impact of fibrates on the differentiation process is very limited. Data obtained by Cimini and colleagues [24] suggested that PPAR’s may be involved in the neural stem cell (NSC) differentiation. The PPARα was shown to be involved in astrocytic differentiation [25] and the PPARβ/δ in the in vitro neuronal maturation [26]. Studies with neuroblastoma cell line demonstrated that PPARβ/δ agonists trigger neuronal differentiation [24]. It is also known that PPARγ are sensors capable of adapting gene expression to integrate various lipid signals; however, PPARα and PPARβ/δ are strongly involved into mitochondrial metabolism through fatty acid oxidation (FAO), thus have impact on mitochondrial metabolism and OXFOS [27].

Our RNA-seq data showed that the PPARα and PPARβ/δ but not PPARγ are expressed in all tested populations including starting population of hiPSC similar to the expression of FASN, the main gene involved in the regulation of fatty acid synthesis. Cimini and colleagues [22] identified a large lipid droplet in the cytoplasm of adult mouse NSC and suggested a role of PPARγ in the NSC differentiation into oligodendrocytes. Since the protocol of neural differentiation used in this study allows to get the cells with neuronal and astrocyte phenotypes, but not oligodendrocytes [11, 12], the lack of PPARγ expression is not surprising. The PPARγ is the important factor which controls adipocyte differentiation as well as in cellular types where lipogenesis occurs, such as oligodendrocytes [28, 29]. In our work, we concentrated mostly on the role of BZ on the PPARGC1A gene expression because earlier data obtained with RNA-seq methods showed the significant differences in the PPARGC1A expression level between compared cell populations. We have also proved that upregulation of PPARGC1A gene by BZ coexists with GFAP early astrocytic and S100B more advanced astrocytic marker upregulation. While GFAP is also the marker of NSC (radial glial cells), it was documented that during development, enhanced S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential [30] and acquire a more mature developmental stage. This nicely correlates with downregulation upon BZ treatment of the advanced neuronal marker MAP2 and the same time upregulation of the DCX, defining the early neuronal marker. Such data strongly suggest
that PPARGC1A plays important role in the mitochondrial biogenesis regulation but also may act independently in the control of neural fate decision.

The mechanism of possible interaction of BZ with PGC-1α pathway is presented in Fig. 9. BZ acts as the agonist/ligand binding to a PPARα receptor, but also can interact with PGC-1α protein, upregulating PPARGC1A (encoding PGC-1α) transcription by independent pathway from PPARα/RXRA complex [31]. The peroxisome proliferator-activated receptors (PPARs) when activated by BZ form heterodimers with the retinoid X receptor (RXR) and after heterodimerization, the complex of PPARα/RXRA bind to specific regions on the DNA of target genes [32] through a PPRE—response element, which is also present in the PGC-1α gene promoter. Increased PGC-1α expression reinforces PPAR activation, therefore triggering a positive autoregulatory loop of the PPAR-PGC-1α axis. The PPARs function as obligate heterodimers with RXR. PPARα, PPARβ/δ, and PPARγ are encoded separately but all of them take part in the regulation of important metabolic pathways [33]. Negative regulation of PPARα/RXR transcription activity is related to recruitment the transcriptional corepressors, for example, NCoR and SMRT, while positive activation is related to recruitment inter alia PGC1-alpha coactivator encoded by PPARGC1A gene [34, 35]. We must emphasize that transcription activity of PPARs during neural differentiation and their role in the neural fate commitment is poorly understood. During hiPSC neural differentiation RXRA, RXRB was expressed in all tested cell types while RXRG was not. The changes in the expression of PPARs and RXRs upon BZ treatment have not been investigated in this study. However, the differences observed by us in the expression of PPARGC1A gene after BZ treatment are strongly suggesting the involvement of this pathway in activation of mitochondrial biogenesis and fate commitment switch observed in this study.

We have confirmed antioxidant capacity of BZ, revealed by a significant decrease of the ROS level and the upregulation of NRF1 gene expression in all tested cell populations [36, 37]. NRF1 is one of the key transcription factors which regulates metabolic and antioxidant genes and modulates mitochondrial DNA transcription and replication [38]. We have shown that BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].

Resting mitochondrial membrane potential was previously linked to the differentiation potential of mESC [41]. mESC with low resting mitochondrial membrane potential had great propensity for in vitro mesodermal differentiation but did not efficiently form teratomas in vivo, whereas mESC with high resting mitochondrial membrane potential favored multi-lineage differentiation. These examples suggest that modulation of mitochondrial biogenesis-related pathways can be a major driving force of cell fate decision during neural differentiation of hiPSC. PPARGC1A expression is induced in response to BZ treatment, which suggests that this mechanism might be involved in PPARα activation and upregulation of PPARGC1A gene transcription. Therefore, BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].

Resting mitochondrial membrane potential was previously linked to the differentiation potential of mESC [41]. mESC with low resting mitochondrial membrane potential had great propensity for in vitro mesodermal differentiation but did not efficiently form teratomas in vivo, whereas mESC with high resting mitochondrial membrane potential favored multi-lineage differentiation. These examples suggest that modulation of mitochondrial biogenesis-related pathways can be a major driving force of cell fate decision during neural differentiation of hiPSC. PPARGC1A expression is induced in response to BZ treatment, which suggests that this mechanism might be involved in PPARα activation and upregulation of PPARGC1A gene transcription. Therefore, BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].

We have confirmed antioxidant capacity of BZ, revealed by a significant decrease of the ROS level and the upregulation of NRF1 gene expression in all tested cell populations [36, 37]. NRF1 is one of the key transcription factors which regulates metabolic and antioxidant genes and modulates mitochondrial DNA transcription and replication [38]. We have shown that BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].

Resting mitochondrial membrane potential was previously linked to the differentiation potential of mESC [41]. mESC with low resting mitochondrial membrane potential had great propensity for in vitro mesodermal differentiation but did not efficiently form teratomas in vivo, whereas mESC with high resting mitochondrial membrane potential favored multi-lineage differentiation. These examples suggest that modulation of mitochondrial biogenesis-related pathways can be a major driving force of cell fate decision during neural differentiation of hiPSC. PPARGC1A expression is induced in response to BZ treatment, which suggests that this mechanism might be involved in PPARα activation and upregulation of PPARGC1A gene transcription. Therefore, BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].

Resting mitochondrial membrane potential was previously linked to the differentiation potential of mESC [41]. mESC with low resting mitochondrial membrane potential had great propensity for in vitro mesodermal differentiation but did not efficiently form teratomas in vivo, whereas mESC with high resting mitochondrial membrane potential favored multi-lineage differentiation. These examples suggest that modulation of mitochondrial biogenesis-related pathways can be a major driving force of cell fate decision during neural differentiation of hiPSC. PPARGC1A expression is induced in response to BZ treatment, which suggests that this mechanism might be involved in PPARα activation and upregulation of PPARGC1A gene transcription. Therefore, BZ treatment upregulates both PPARGC1A and NRF1 during neural differentiation of hiPSC. Documented interference of those two factors is crucial to antioxidant defense and redox balance. Reduction of ROS in NP stage was accompanied by increase in the mitochondrial membrane potential and this relation is typical for other cellular systems [39, 40].
membrane potential can influence the cell fate decision. In our study, we have observed downregulation of mature neuron MAP2 and early astrocytic GFAP marker and the same time strong upregulation of early neuronal marker DCX and mature astrocytic S100B in NP stage in relation to the significant increase of mitochondrial membrane potential induced by BZ. The role of increased of mitochondrial membrane potential upon BZ treatment at NP in the induction of mitochondrial biogenesis is still to be elucidated.

One of the main goals of mitochondrial disease therapy is to improve mitochondrial function by increasing the number of mitochondria [42]. We demonstrated that the treatment with BZ increased mitochondrial biogenesis by all tested factors (significant upregulation of SDHA and COX1 protein expression, NRF1, TFAM, PPARGC1A gene expression, and increased mtDNA copy number only in NP stage of hiPSC neural differentiation). This was not related to the cell viability, which was not changed by BZ at this stage of development.

The expression of two proteins important for mitochondrial function: SDHA and COX-1, was measured as one of the indicators of mitochondrial biogenesis. SDHA is major catalytic subunit of succinate-ubiquinone oxidoreductase [43], a complex of the mitochondrial respiratory chain, while COX1 is the component of the respiratory chain that catalyzes the reduction of oxygen to water [44]. We have shown a significant increase of SDHA and COX-1 expression upon BZ treatment in eNP and NP stages, which may indicate a positive drug effect on mitochondria functionality. The level of mtDNA copy number was the second indicator of mitochondrial biogenesis. We detected a significant increase of mtDNA copy number upon BZ treatment but only at the NP stage of development.

In addition, our data indicate that only at NP stage the upregulation of TFAM expression after BZ treatment is concomitant with an increase in mitochondrial DNA copy number. The developmental stage-specific relation of the increase in TFAM expression and mtDNA copy level was also demonstrated after exposition to PQQ and IDB but in these cases at the eNP stage of development [11, 12]. In conclusion, we have shown that regulation of mitochondrial biogenesis by TFAM in hiPSC is modified by selected drugs in neural stage development-dependent manner.

Through the recent studies of our group, we have observed an interesting molecular relationship of the expression of selected genes important for mitochondrial biogenesis with the expression of genes typical for neuronal and astrocytic differentiation. In that respect, the most important result in our study seems to be the upregulation of the expression of PPARGC1A-encoded coactivator PPARs-PGC-1α, which is known to activate NRF1/2, PPAR, YY1, and ERR transcription factors, controlling key mitochondrial genes (OXPHOS subunits, Krebs cycle enzymes, fatty acid β-oxidation, proteins involved in mitochondrial protein import and assembly) [45]. The highest upregulation of PPARGC1A upon BZ treatment was observed at the NSC and eNP stage of differentiation and as mentioned above accompanied by upregulation of GFAP and S100B. GFAP gene expression was confirmed also in the case of other drugs tested by our group (PQQ, IDB) [11, 12].

Surprisingly in this study, the increase of mitochondria biogenesis measured by all tested factors (protein expression, mtDNA copy number, and expression of selected genes, linked to mitochondria function) for the NP stage of differentiation was accompanied with upregulation of early neuronal DCX and mature astrocyte S100B markers. Induction of mitochondrial biogenesis, dependent upon the stage of hiPSC neural differentiation, was shown by our group in the case of PQQ [11] and IDB [12], but only at eNP, not at NSC and NP stages of development and this coexists with astrocytic fate commitment.

Further studies are needed to explain the molecular mechanisms of developmental stage-specific induction of mitochondrial biogenesis and the neural fate specification. We think that the defined cellular “metabolic state” is necessary to induce mitochondrial biogenesis; therefore, stimulation of mitochondrial biogenesis was not observed at the NSC stage exposed to PQQ [11] and IDB [12] as well as BZ in this study. However, BZ was efficient at the more advanced stage of differentiation (NP) than other drugs.

One of the explanations is that the mechanisms of action of PQQ [46] and IDB [47] are antioxidant-related, while BZ regulates fatty acid metabolism. IDB and PQQ belong to an antioxidant group, while BZ impact on mitochondria is related to its caloric restriction functions [48]. PQQ [11] and IDB [12] induced the strongest mitochondrial biogenesis at the stage eNP, while BZ at the stage of NP. One of the potential reasons that BZ is effective in NP stage to induce mitochondrial biogenesis can be a fact that proliferating neural progenitors at this stage contain high levels of fatty acid synthase [49]. Activation of acetyl-CoA (Ac-CoA) carboxylase (ACC) and fatty acid synthase (FASN) at neural progenitors increase fatty acid synthesis from Ac-CoA to fuel phospholipid membrane synthesis [50].

In conclusion, in our study, the expression of receptor PPARα is on the highest level as compared to other PPARs in all tested cell populations. PPARγ and RXRγ play potentially important role in the oligodendrocyte differentiation. Lack of expression of these receptors coexists with lack of oligodendrocytic phenotypes. Our results indicated that upon BZ treatment, modification of neural cell fate decision is linked to the induction of mitochondrial biogenesis (upregulation of S100B and downregulation of MAP2 at NP stage) but not for all tested differentiation markers (e.g., GFAP). For the differentiation switch, PGC-1α and PPAR signaling pathway seems to play the crucial role: elevated expression of astroglial markers GFAP and S100B and downregulation of MAP2 always coexist with upregulation of PPARGC1A. Thus, the possible way of action of BZ in activation of astrocytogenesis is through the pathway dependent from PGC-1α and PPARα.
One of the most important results in our study seems to be the upregulation of the expression of all tested genes as well as protein markers crucial for mitochondria function only in NP stage of development. Thus, we have confirmed that the positive effect of BZ on mitochondrial biogenesis is dependent on neural stem cell stage of differentiation. However, it is suggested that for the control of neural fate decision, the mutual interplay between mitochondrial biogenesis, PPAR receptor activity, and maturity of mitochondria are required. Our study indicates a new potential use of BZ as the stimulant of mitochondrial dysfunction. To the best of our knowledge, we provided the first study investigating BZ role in neural fate commitment modulation.

**Funding Information** This work was supported by the National Science Center grant number 2013/11/B/NT1/00089 (to PPS), Wrocław Research Centre EIT+, grant BioMed/3.4 POIG.01.01.02-02-003/08 (to LB), and the statutory funds to the Mossakowski Medical Research Centre.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Olsson AG, Lang PD (1978) One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 31:429–433. https://doi.org/10.1016/0021-9150(78)90138-7
2. Shipman KE, Strange RC, Ramachandran S (2016) Use of fibrates in the metabolic syndrome: a review. World J Diabetes 7:74. https://doi.org/10.4239/wjd.v7.i5.74
3. Fruchart JC, Duriez P (2006) Mode of action of fibrates in the metabolic syndrome: a review. World J Diabetes 7:74–88. https://doi.org/10.4239/wjd.v7.i5.74
4. Johri A, Chandra A, Beal MF (2013) PGC-1α, mitochondrial dysfunction, and Huntington’s disease. Free Radic Biol Med 62:37–46. https://doi.org/10.1016/j.freeradbiomed.2013.04.016
5. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 24:1119–1131. https://doi.org/10.1089/neu.2006.0216
6. Hondares E, Mora O, Yubero P, De La Concepción MR, Iglesias R, Giralt M, Villarroya F (2006) Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1α gene transcription: an autoregulatory loop controls PGC-1α expression in adipocytes via peroxisome proliferator-activated receptor-γ coactivation. Endocrinology 147:2829–2838. https://doi.org/10.1210/en.2006-0070
7. Hondares E, Pineda-Torra I, Iglesias R, Staels B, Villarroya F, Giralt M (2007) PPARdelta, but not PPARalpha, activates PGC-1α gene transcription in muscle. Biochem Biophys Res Commun 354:1021–1027. https://doi.org/10.1016/j.bbrc.2007.01.092
8. Hondares E, Rosell M, Diaz-Delfin J, Olmos Y, Monsalve M, Iglesias R, Villarroya F, Giralt M (2011) Peroxisome proliferator-activated receptor α (PPARα) induces PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16. J Biol Chem 286:43112–43122. https://doi.org/10.1074/jbc.M111.252775
9. Szabolowska-Gadomska I, Syepecka J, Zayat V, Potobinska M, Pastwinska A, Pienkowska-Grela B, Buzanska L (2012) Treatment with small molecules is an important milestone towards the induction of pluripotency in neural stem cells derived from human cord blood. Acta Neurobiol Exp (Wars) 72:337–350
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. https://doi.org/10.1016/j.cell.2007.11.019
11. Augustyniak J, Lenart J, Zychowicz M, Lipka G, Gaj P, Kolanowska M, Stepien PP, Buzanska L (2017a) Sensitivity of hiPS-derived neural stem cells (NSC) to pyroloquinoline quinone depends on their developmental stage. Toxicol Vitr 45:434–444. https://doi.org/10.1016/j.tvit.2017.05.017
12. Augustyniak J, Lenart J, Zychowicz M, Stepien PP, Buzanska L (2017b) Mitochondrial biogenesis and neural differentiation of human iPSC is modulated by idebenone in a developmental stage-dependent manner. Biogerontology 18:665–677. https://doi.org/10.1007/s10522-017-9718-4
13. Yan Y, Shin S, Jha BS, Liu Q, Sheng J, Li F, Zhan M, Davis J et al (2013) Efficient and rapid derivation of primitive neural stem cells and generation of brain subtype neurons from human pluripotent stem cells. Stem Cells Transl Med 2:862–870. https://doi.org/10.5966/sctm.2013-0080
14. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:454–456. https://doi.org/10.1093/nar.29.9.e45
15. Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170
16. Dobin A, Davis CA, Schroesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Caisson M et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. https://doi.org/10.1093/bioinformatics/bts635
17. Anders S, Pyl PT, Huber W (2015) HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169. https://doi.org/10.1093/bioinformatics/btu638
18. Tange, O., 2011. GNU parallel: the command-line power tool. ;login 36:1–6. https://doi.org/10.5281/zenodo.16303
19. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a biocomputer package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140. https://doi.org/10.1093/bioinformatics/btp616
20. Xing F, Luan Y, Cai J, Wu S, Mai J, Zhang H, Li K et al (2017) The anti-Warburg effect elicited by the cAMP-PGC1α pathway drives differentiation of glioblastoma cells into astrocytes. Cell Rep 18:468–481. https://doi.org/10.1016/j.celrep.2016.12.037
21. Vanet A, Arnold T, Najimi M, Renard P (2015) Connecting mitochondria, metabolism, and stem cell fate. Stem Cells Dev 24:1957–1971. https://doi.org/10.1089/scd.2015.0117
22. Cimmini L, Cristiano L, Benedetti E, D’Angelo B, Cerù MP (2007) PPARs expression in adult mouse neural stem cells: modulation of PPARs during astroglial differentiation of NSC. PPAR Res doi 2007:1–10. https://doi.org/10.1155/2007/48242
23. Villena JA (2015) New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J 282:647–672. https://doi.org/10.1111/febs.13175

24. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D’Amico MA, D’Angelo B, Di Loreto S (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130:325–337. https://doi.org/10.1016/j.neuroscience.2004.09.043

25. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the cross-roads of key cellular functions. Prog Lipid Res 45:120–159. https://doi.org/10.1016/j.plipres.2005.12.002

26. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Fan W, Evans R (2015) PPARs and ERRs: molecular mediators of their role in the regulation of mitochondrial function and beyond. FEBS J 282:647–672. https://doi.org/10.1111/febs.13175

27. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Fan W, Evans R (2015) PPARs and ERRs: molecular mediators of their role in the regulation of mitochondrial function and beyond. FEBS J 282:647–672. https://doi.org/10.1111/febs.13175

28. Berger JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the cross-roads of key cellular functions. Prog Lipid Res 45:120–159. https://doi.org/10.1016/j.plipres.2005.12.002

29. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong 25. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the cross-roads of key cellular functions. Prog Lipid Res 45:120–159. https://doi.org/10.1016/j.plipres.2005.12.002

30. Raponi E, Agenes F, Delphin C, Assard N, Baudier J, Legraverend C, Deloulme JC (2007) S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 55:165–177. https://doi.org/10.1111/j.1468-011X.2007.01319.x

31. Shiuie Y-L, Chen L-R, Tsai C-J, Yeh C-Y, Huang C-T (2013) Emerging roles of peroxisome proliferator-activated receptor agonists in the pituitary gland in female reproduction. Biomarkers and Genomic Medicine 5:1–11. https://doi.org/10.1155/2013/572481

32. Maire A, Alvarez S, Shankaranarayanan P, Lera AR, Bourguet W, Gronemeyer H (2012) Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem 12:505–527. https://doi.org/10.2174/156802612798156139

33. Chandra V, Huang P, Hamuro Y, Raghurom S, Wang Y, Burris TP, Rastinejad F (2008) Structure of the intact PPAR-gamma-RXR-α receptor complex on DNA. Nature 456:350–356. https://doi.org/10.1038/nature07413

34. Semple RK, Meihaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK et al (2005 Apr) A dominant negative human peroxisome proliferator-activated receptor (PPAR[alpha]) is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology 146(4):1871–1882 Epub 2005 Jan 20

35. Yu S, Reddy JK (2007) Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 1771(8): 936–951. https://doi.org/10.1016/j.bbabio.2007.01.008

36. Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, Komoda T, Katayama S (1998) Beazafibrate has an antioxidant effect: peroxisome proliferator-activated receptor α is associated with Cu2+, Zn2+–superoxide dismutase in the liver. Life Sci 63:135– 144. https://doi.org/10.1016/S0024-2205(98)00249-5

37. Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C, Sesaki H, Lagace DC et al (2016) Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell 19:232–247. https://doi.org/10.1016/j.stem.2016.04.015

38. Jacob W, Silverman TA, Cohen RB, Safer B (1989) Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 alpha. J Biol Chem 264:20372–20384

39. Husa J, Lebedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR (2012) Relation between mitochondrial membrane potential and ROS formation. Methods Mol Biol 810:183–205. https://doi.org/10.1007/978-1-61779-382-0_12

40. Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94:909–950. https://doi.org/10.1152/physrev.00026.2013

41. Schieke SM, Ma M, Cao L, McCoy JP, Liu C, Hensel NF, Barrett AJ, Boehm M et al (2008) Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J Biol Chem 283:28506–28512. https://doi.org/10.1074/jbc.M802763200

42. Nightingale H, Pfeffer B, Bargiela D, Horvath R, Chinnery PF (2016) Emerging therapies for mitochondrial disorders. Brain 139:1633–1648. https://doi.org/10.1093/brain/awv081

43. Hirawake H, Wang H, Kuramochi T, Kojima S, Kita K (1994) Human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of the flavoprotein (Fp) subunit of liver mitochondria. J Biochem 116:221–227

44. Anderson S, Bankier AT, Barrett BG, de Bruijn NC, Coulson AR, Drouin J, Eperon IC, Nierlich DP et al (1981) Sequence and organization of the human mitochondrial genome. Nature 290:457–465. https://doi.org/10.1038/309457a0

45. Kanabus M, Heales SJ, Rahman S (2014) Development of pharmacological strategies for mitochondrial disorders. Br J Pharmacol 171:1798–1817. https://doi.org/10.1111/bph.12456

46. Harris CB, Chowanadisai W, Misshuk DO, Satte MA, Slupska CM, Ruck RB (2013) Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem 24:2076–2084. https://doi.org/10.1016/j.jnutbio.2013.07.008

47. McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA 2nd, Maibach HI (2005) Idebenone: a new antioxidant—part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cutan Pharmacol 4:10–17. https://doi.org/10.1111/j.1473-2165.2005.00152.x

48. Komen JC, Thorburn DR (2014) Turn up the power—pharmacological activation of mitochondrial biogenesis in mouse models. Br J Pharmacol 171:1818–1836. https://doi.org/10.1111/bph.12413

49. Komoda T, Katayama S (1998) Bezafibrate has an antioxidant ef- fect: peroxisome proliferator-activated receptor, FEBS J 282:647– 672. https://doi.org/10.1111/febs.13175

50. Komoda T, Katayama S (1998) Bezafibrate has an antioxidant ef- fect: peroxisome proliferator-activated receptor, FEBS J 282:647– 672. https://doi.org/10.1111/febs.13175